Binding antibody against primary HIV-1 isolates induced in recipients of recombinant envelope glycoprotein HIV-1 candidate vaccines (MN/rgp120 and IIIB/rgp120).

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Binding antibody against primary HIV-1 isolates induced in recipients of recombinant envelope glycoprotein HIV-1 candidate vaccines (MN/rgp120 and IIIB/rgp120).

Conf Adv AIDS Vaccine Dev. 1997 May 4-7;:54. Unique Identifier : AIDSLINE MED/97927038
Gorse GJ; Patel GB; Mandava M; Berman PW; Belshe RB; Saint Louis University Health Sciences Center, St. Louis, MO. Fax:; (314) 771-3816.

Abstract: Induction of binding antibody to native envelope glycoproteins of primary HIV-1 isolates by MN/- and IIIB/rgp120 vaccines in alum was evaluated. A flow cytometric indirect immunofluorescence assay was used to measure the binding of serum antibodies to PBL's infected with primary HIV-1 isolates. Sera were obtained before and after vaccination of 27 normal, healthy, HIV-1 uninfected adults, who received one of four immunization regimens or placebo: 1) MN/rgp120 vaccine alone, 2) MN/rgp120 vaccine co-administered with IIIB/rgp120 vaccine, 3) IIIB/rgp120 vaccine alone, 4) priming with IIIB/rgp120 vaccine followed by boosting with MN/rgp120 vaccine, or 5) adjuvant placebo. Six clade B 92US727, 92US714, 92US657, 92US660, 91US056, BZ167), one clade A 92UG029), and one clade EA (92TH022) primary HIV-1 isolates were studied. Positive control sera from HIV-1-infected non-vaccinees who acquired HIV-1 infection in the US had high levels of antibody against all eight primary HIV-1 isolates. All 15 vaccinees who received regimens (1) and (2) made antibodies against four clade B viruses at levels half that of the infected patient sera and as high as infected patients against 91US056. Antibodies to BZ167, 92UG029 and 92TH022 were detected in sera from about 25% to 50% of vaccinees in regimens (1) and (2), but at lower levels compared to infected patients. Vaccinees who received IIIB/rgp120 vaccine alone developed lower levels of antibody against clade B viruses; these increased after MN/rgp120 vaccine boosting. The MN/rgp120 vaccine was an effective inducer of cross-reactive antibodies against envelope glycoproteins of several HIV-1 strains, and it boosted the lower antibody response induced by immunization with only IIIB/rgp120.

Keywords: *AIDS Vaccines/IMMUNOLOGY *HIV Antibodies/IMMUNOLOGY *HIV Envelope Protein gp120/IMMUNOLOGY *HIV-1/IMMUNOLOGY
971130
M97B1185

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .